Roche completes purchase agreement with long-term partner TIB Molbiol to expand PCR-test portfolio in the fight against new infectious diseases

Basel, 1 December  2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced it has completed its share purchase agreement to acquire 100 percent of the outstanding shares of TIB Molbiol Group. TIB Molbiol will continue to operate as a subsidiary within the Diagnostics division. Roche and TIB Molbiol will build on t heir capabilities for the rapid development of assays for emerging pathogens and potential health threats, such as infectious diseases.
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news